⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Supplementary Figure 2 from AMT-562, a novel HER3-targeting antibody drug conjugate, demonstrates a potential to broaden therapeutic opportunities for HER3-expressing tumors

Weining Weng Tao Meng Junyi Pu Linjie Ma Yi Shen Zhaohui Wang Rong Pan Mingqiao Wang Caiwei Chen Lijun Wang Jianjian Zhang Biao Zhou Siyuan Shao Yu Qian Shu-Hui Liu Wenhao Hu Xun Meng

View at Publisher

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

HER3 expression level and hydrophilicity of Ab562 ADCs.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Weng et al. (2024) studied this question.

synapsesocial.com/papers/68e58589b6db643587522605 https://doi.org/10.1158/1535-7163.27036175

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 2 from AMT-562, a novel HER3-targeting antibody drug conjugate, demonstrates a potential to broaden therapeutic opportunities for HER3-expressing tumors2024
2Supplementary Figure 1 from AMT-562, a novel HER3-targeting antibody drug conjugate, demonstrates a potential to broaden therapeutic opportunities for HER3-expressing tumors2024
3Supplementary Figure 1 from AMT-562, a novel HER3-targeting antibody drug conjugate, demonstrates a potential to broaden therapeutic opportunities for HER3-expressing tumors2024
4Supplementary Figure 6 from AMT-562, a novel HER3-targeting antibody drug conjugate, demonstrates a potential to broaden therapeutic opportunities for HER3-expressing tumors2024
5Supplementary Figure 6 from AMT-562, a novel HER3-targeting antibody drug conjugate, demonstrates a potential to broaden therapeutic opportunities for HER3-expressing tumors2024
6Supplementary Figure 7 from AMT-562, a novel HER3-targeting antibody drug conjugate, demonstrates a potential to broaden therapeutic opportunities for HER3-expressing tumors2024
7Supplementary Figure 7 from AMT-562, a novel HER3-targeting antibody drug conjugate, demonstrates a potential to broaden therapeutic opportunities for HER3-expressing tumors2024
8Supplementary Figure 5 from AMT-562, a novel HER3-targeting antibody drug conjugate, demonstrates a potential to broaden therapeutic opportunities for HER3-expressing tumors2024